Harleysville, PA, United States of America

Mark W Embrey

USPTO Granted Patents = 19 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 7.4

ph-index = 6

Forward Citations = 222(Granted Patents)

Location History:

North Wales, PA (US) (1999 - 2008)
Harleysville, PA (US) (2009 - 2024)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

2 out of 28

Ra Pharmaceuticals, Inc.

patents

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12012468 - Cyclic polypeptides for PCSK9 inhibition (2024-06-18),

2. 11530244 - Cyclic polypeptides for PCSK9 inhibition (2022-12-20),

3. 11413292 - Tricyclic heterocycle compounds useful as HIV integrase inhibitors (2022-08-16),

4. 10221186 - Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors (2019-03-05),

5. 10150780 - Spirocyclic heterocycle compounds useful as HIV integrase inhibitors (2018-12-11),

6. 9951079 - Fused tricyclic heterocyclic compounds as HIV integrase inhibitors (2018-04-24),

7. 9714243 - 4-pyridinonetriazine derivatives as HIV integrase inhibitors (2017-07-25),

8. 9707234 - Spirocyclic hetercycle compounds useful as HIV integrase inhibitors (2017-07-18),

9. 8513234 - HIV integrase inhibitors (2013-08-20),

10. 7820680 - HIV integrase inhibitors (2010-10-26),

11. 7538112 - HIV integrase inhibitors (2009-05-26),

12. 7435735 - Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors (2008-10-14),

13. 7323460 - N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors (2008-01-29),

14. 6921759 - Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors (2005-07-26),

15. 6380249 - HIV integrase inhibitors (2002-04-30),

Hello! I'm pleased to present an article on the innovative inventor Mark W Embrey, hailing from Harleysville, PA (US), with an impressive 18 patents under his belt.

Latest Patents:

Embrey's latest patents showcase his groundbreaking work in the field of pharmaceuticals. One notable invention is cyclic polypeptides for PCSK9 inhibition, designed to reduce LDL cholesterol levels in individuals. Another significant patent involves tricyclic heterocycle compounds utilized as HIV integrase inhibitors. These inventions highlight his dedication to advancing healthcare through innovative solutions.

Career Highlights:

Embrey has left a mark at renowned companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His contributions have undoubtedly shaped the pharmaceutical industry, demonstrating his expertise and commitment to driving progress.

Collaborations:

Throughout his career, Embrey has collaborated with esteemed professionals like John S Wai and Thorsten E Fisher. These collaborations have fostered a culture of innovation, allowing for the exchange of ideas and the development of groundbreaking solutions in the field of pharmaceuticals.

In conclusion, Mark W Embrey's exceptional work in the pharmaceutical sector has not only led to numerous patents but has also contributed significantly to the advancement of healthcare. His collaborations and career highlights exemplify his dedication to innovation, making him a standout figure in the industry.

This text is generated by artificial intelligence and may not be accurate.